The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AND | +32.79% | +27.89% | +5.04% | +184% |
| S&P | +16.9% | +95.99% | +14.39% | +116% |
Andlauer Healthcare Group, Inc. is a supply chain management company with a platform of customized third-party logistics (3PL) and specialized transportation solutions for the healthcare sector. It offer services to healthcare, manufacturers, wholesalers, distributors and 3PL providers, among others, through a comprehensive platform of technology-enabled supply chain solutions for a range of products, including pharmaceuticals, biologics, narcotics, precursors, active pharmaceutical ingredients ,over-the-counter, natural health, animal health, consumer health, cosmetics, health and beauty aids and medical devices. It operates through the following segments: Specialized Transportation and Healthcare Logistics. The Healthcare Logistics segment provides supply chain services for its customers, including logistics and distribution services and packaging solutions. The Specialized Transportation segment includes air freight forwarding, ground transportation and dedicated and last mile delivery product lines. The company was founded in 1991 and is headquartered in Vaughan, Canada.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $156.60M | -3.0% |
| Gross Profit | $35.80M | -1.7% |
| Gross Margin | 22.86% | 0.3% |
| Market Cap | $2.06B | 28.4% |
| Market Cap / Employee | $0.87M | 0.0% |
| Employees | 2.4K | 3.9% |
| Net Income | $13.45M | -14.5% |
| EBITDA | $36.87M | -7.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $58.98M | 44.8% |
| Accounts Receivable | $88.02M | -9.8% |
| Inventory | 5.8 | -0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $90.58M | -9.1% |
| Short Term Debt | $87.56M | 25.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.03% | 0.6% |
| Return On Invested Capital | 14.61% | -1.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $31.19M | -14.1% |
| Operating Free Cash Flow | $35.92M | -5.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 24.31 | 26.32 | 22.18 | 30.61 | 22.75% |
| Price to Book | 3.81 | 4.10 | 3.55 | 4.64 | 38.91% |
| Price to Sales | 2.39 | 2.58 | 2.37 | 3.22 | 28.79% |
| Price to Tangible Book Value | 21.41 | 20.98 | 15.71 | 17.76 | 60.61% |
| Price to Free Cash Flow TTM | 17.42 | 18.65 | 17.17 | 24.74 | 32.27% |
| Enterprise Value to EBITDA | 40.83 | 41.07 | 42.85 | 60.04 | 36.52% |
| Free Cash Flow Yield | 5.7% | 5.4% | 5.8% | 4.0% | -24.40% |
| Return on Equity | 14.9% | 14.3% | 15.1% | 16.0% | 7.27% |
| Total Debt | $158.97M | $181.21M | $182.60M | $178.14M | 5.33% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
